The Global Spinal
Muscular Atrophy (SMA) Market, by Disease Type (Type I, Type II, Type III,
Type IV) Treatment (Gene Therapy and Drugs), by Age (Infant and Adult),and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) was estimated to be valued at US$ 884 million in 2017 and is projected
to exhibit a CAGR of 12.4% over the forecast period (2018 – 2026). Spinal
muscular atrophy market is expected to grow at significant rate, owing to
rising number of clinical trials being conducted to develop effective treatment
for the disease.
Increasing focus on clinical
trials is expected to drive growth of the spinal muscular atrophy (SMA) market
Increasing number of clinical
trials are being conducted by key industry players and rising government
support for these clinical trials is expected to drive growth of the spinal
muscular atrophy market. Various clinical studies focus on therapeutic
strategies to increase survival motor neuron (SMN) protein in motor neurons
since these neurons control muscle movement in the body. SMN protein is
important for maintenance of motor neurons, which are located in the spinal
cord and brainstem, the part of the brain that is connected to the spinal cord.
Currently, only one approved drug
treatment is available for spinal muscular atrophy i.e. Spinraza. In 2016, the
U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of
SMA. Spinraza targets the underlying defect in SMA, so it can help prevent, delay,
or even reverse the symptoms. However, its common side effects include higher
risk of constipation and respiratory tract infection along with minimal risk of
kidney problems and bleeding.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1920
Several biotechnology and
biopharmaceutical giants are working towards developing effective treatment for
SMA. For instance, in 2017, AveXis received FDA approval for manufacturing of
AVXS-101 gene therapy. It is currently in development stage, and has been
granted Orphan Drug Designation in 2017 for the treatment of all types of
spinal muscular atrophy (SMA) and Breakthrough Therapy Designation in 2016 for
the same. It also received Fast Track Designation in 2016, for the treatment of
SMA Type 1—one of the most chronic neurological genetic disorders.
In April 2018, AveXis announced
launching of a Phase 3 trial, for STR1VE in infants with SMA type 1. AveXis
also plans to initiate a similar trial in Europe called STR1VE EU.
Browse 32 Market Data Tables and
26 Figures spread through 161 Pages and in-depth TOC on “Spinal Muscular
Atrophy Market, by Disease Type (Type I, Type II, Type III, Type IV), by
Treatment (Gene Therapy and Drugs), by Age (Infant and Adult), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Global Forecast to 2026”
Key players are focusing on
mergers and acquisitions, new product launches, and partnerships, in order to
enhance their share in the market. For instance, in 2016, Ionis discovered
Spinraza and co-developed the drug with Biogen. Ionis received a payment of US$
320 million from Biogen for the development of Spinraza till the year 2016,
including US$ 90 million based on regulatory approvals in Japan and Europe.
Another key player Roche, acquired Trophos in 2015 with the intent of
continuing clinical trials for Olesoxime. The company is currently planning a
Phase 3 study enrolling individuals with SMA type II or III.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/spinal-muscular-atrophy-market-1920
Key Takeaways of the Spinal
Muscular Atrophy Market:
The global spinal muscular
atrophy market is expected to exhibit a CAGR of 12.4% over the forecast period,
owing to rising number of clinical trials for development of new therapies.
Among treatment, the drugs
segment is estimated to hold the dominant position in the spinal muscular
atrophy market in 2017 due to approval of single drug Spinraza.
Among disease type, the type I
segment is estimated to hold the dominant position in the spinal muscular
atrophy market in 2017. This is owing to it been the most common and severe
form of SMA. According to SMA Europe 2015 data, type I accounts for 50% to 70%
of cases of childhood onset SMA.
North America held a dominant
position in 2017 owing to higher demand for spinal muscular atrophy treatment
as a result of higher diagnosis rate in the region.
Key players operating in the
global spinal muscular atrophy market include Biogen, Cytokinetics, Inc., F.
Hoffmann-La Roche, Novartis AG, Pfizer, and Ionis Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1920
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment